Objective To evaluate the therapeutic response and associated factors of chemotherapy plus immune checkpoint inhibitors in patients with different subtypes of esophageal cancer (EC). Methods A total of 148 patients with EC admitted from January 2020 to January 2025 were enrolled as research subjects. They were classified into four subtypes based on endoscopic findings: occult type (congestive type), erosive type, plaque type, and papillary type. The therapeutic effects of chemotherapy combined with immune checkpoint inhibitors in patients with different EC subtypes were evaluated in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST). Furthermore, the patients were divided into a response group and a non-response group according to the therapeutic effects. Univariate analysis and multivariate binary logistic regression analysis were performed to identify independent influencing factors, and receiver operating characteristic (ROC) curves were plotted to calculate the area under the curve (AUC) for evaluating the predictive value of these factors on therapeutic outcomes. Results A total of 99 EC patients responded to chemotherapy combined with immune checkpoint inhibitors, with a response rate of 66.89% (99/148). There was a statistically significant difference in therapeutic outcomes among EC patients with different endoscopic subtypes. Multivariate analysis showed that well differentiation (OR=16.026), erosive type (OR=32.331), plaque type (OR=17.506), leukopenia (OR=9.639), erythrocytopenia (OR=17.638), neutropenia (OR=9.177), transaminase abnormality (OR=5.847), and creatinine abnormality (OR=3.777) were independent risk factors for non-response to the combined therapy in EC patients. The AUC of the combined prediction model was 0.944, with a sensitivity of 0.959, and a specificity of 0.848, indicating that its predictive ability was superior to that of each single indicator. Conclusion The response rate of EC patients to chemotherapy combined with immunotherapy was 66.89%, indicating a favorable short-term therapeutic effect; however, therapeutic outcomes varied among EC patients with different endoscopic subtypes. For the erosive subtype, which showed a poor response to the combined treatment, adjustment of the therapeutic regimen may be necessary to enhance treatment efficacy.
Key words
esophageal cancer /
immune checkpoint inhibitors /
chemotherapy
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] ZENG H, ZHENG R, SUN K, et al.Cancer survival statistics in China 2019-2021: a multicenter, population-based study[J]. J Natl Cancer Cent, 2024, 4(3): 203-213.
[2] LI ZC, SUN YT, LAI MY, et al.Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: a systematic review and network meta-analysis[J]. Int Immunopharmacol, 2022, 109: 108790.
[3] SHI F, HE Z, SU H, et al.Economic evaluation of tislelizumab versus chemother-apy as second-line treatment for advanced or metastatic esophageal squamous cell car-cinoma in China[J]. Front Pharmacol, 2022, 13: 961347.
[4] 李家贺, 卢佳煜, 张旭旭, 等.2025年美国临床肿瘤学会胃肠道肿瘤研讨会 (ASCO-GI) 食管癌及胃食管结合部癌治疗进展解读[J]. 中国胸心血管外科临床杂志, 2025, 32(06): 771-778.
[5] 郑子钰, 王鑫. 食管癌综合治疗进展[J]. 中国肿瘤临床, 2025, 52(06): 298-303.
[6] Montagnani F, Fornaro L, Frumento P, et al.Multimodality treatment of locally advanced squamous cell carcinoma of the oesophagus: a comprehensive review and network meta-analysis[J]. Crit Rev Oncol Hematol, 2017, 114: 24-32.
[7] 中华人民共和国国家卫生健康委员会医政医管局. 食管癌诊疗指南 (2022年版)[J]. 中华消化外科杂志, 2022, 21(10): 1247-1268.
[8] 刘娅, 邓红彬. 实体瘤免疫治疗的非常规反应及其疗效评价标准的研究进展[J]. 中国肿瘤生物治疗杂志, 2020, 27(06): 698-704.
[9] HAN B, ZHENG R, ZENG H, et al.Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53.
[10] KOJIMA T, SHAH MA, MURO K, et al.Randomized Phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer[J]. Clin Oncol, 2020, 38(35): 4138-4148.
[11] WU J, QIN Y, LI K, et al.Recurrence patterns and long-term survival of locally advanced esophageal cancer patients with pathological complete response after different neoadjuvant therapies followed by surgery[J]. BMC Cancer, 2025, 25(1): 1135.
[12] FUJIYOSHI MRA, INOUE H, FUJIYOSHI Y, et al.Endoscopic classifications of early gastric cancer: a literature review[J]. Cancers, 2021, 14(1): 100.
[13] 舒炜阳, 石岩岩, 李渊. 浅表食管鳞状细胞癌浸润深度的内镜诊断进展[J]. 中国医学前沿杂志 (电子版), 2024, 16(03): 83-90.
[14] 周美艳, 高家驹. 老年食管癌内镜分型与肿瘤浸润深度、方式、转移及术后疗效的相关性[J]. 中国老年学杂志, 2020, 40(21): 4534-4537.
[15] XIE Y, LIN J, ZHANG N, et al. Prevalent pseudoprogression and pseudoresidue in patients with rectal cancer treated with neoadjuvant immune checkpoint inhibitors[J]. J Natl Compr Canc Netw, 2023, 21(2): 133-142. e3.
[16] 吴珊珊, 谢晓纯, 黄晓杰, 等. 晚期食管鳞癌患者接受免疫检查点抑制剂治疗的疗效及预后影响因素分析[J]. 中国医院药学杂志, 2024, 44(10): 1199-1204.
[17] CATALANO M, IANNONE LF, NESI G, et al.Immunotherapy-related biomarkers: confirmations and uncertainties[J]. Crit Rev Oncol Hematol, 2023, 192: 104135.
[18] DARRAGH LB, KARAM SD.Amateur antigen-presenting cells in the tumor micro-environment[J]. Mol Carcinog, 2022, 61(2): 153-164.
[19] WEI C, MA Y, WANG F, et al.Igniting hope for tumor immunotherapy: promoting the “hot and cold” tumor transition[J]. Clin Med Insights Oncol, 2022, 16: 11795549221120708.
[20] LI J, STANGER BZ.How tumor cell dedifferentiation drives immune evasion and resistance to immunotherapy[J]. Cancer Res, 2020, 80(19): 4037-4041.
[21] LIU Y, BAO Y, YANG X, et al.Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: a systematic review and meta-analysis[J]. Front Immunol, 2023, 14: 1117448.
[22] 韩光锋, 李承慧. 沙利度胺联合同步放、化疗治疗不宜手术食管癌的疗效和不良反应[J]. 现代肿瘤医学, 2022, 30(16): 2929-2932.
[23] 孙志伟, 贾军, 杨颖, 等. 肠内营养支持治疗减轻晚期食管癌患者化疗不良反应[J]. 北京大学学报 (医学版), 2020, 52(02): 261-268.